CD45 MicroBeads were developed for the positive selection or depletion of leukocytes from peripheral blood, erythrocyte and thrombocyte preparations, lymphoid tissues, as well as nonhematopoietic tissues.
Related products for CD45 MicroBeads, human
CD45 MicroBeads were developed for the positive selection or depletion of leukocytes from peripheral blood, erythrocyte and thrombocyte preparations, lymphoid tissues, as well as nonhematopoietic tissues.
The CD45 antigen is expressed on all cells of hematopoietic origin except erythrocytes, platelets, and their precursor cells.
CD45 MicroBeads have been used to enrich fetal erythroblasts from maternal blood. They were also used to enrich epithelial tumor cells from peripheral blood, bone marrow, or lymphoid tissue by depletion of CD45+ leukocytes1. Stem cells from human bone marrow have been enriched by depletion of cells labeled with CD235a (Glycophorin A) MicroBeads and CD45 MicroBeads.2 Furthermore, CD45 MicroBeads have been used in xenogeneic engraftment studies for the isolation of CD45+ leukocytes.
For positive selection: MS, LS, XS, or autoMACS® Columns. For depletion: LD, D, or autoMACS Columns.
Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC.
A cytokeratin-positive cell was enriched from bone marrow of a patient with renal carcinoma by depletion of leukocytes using CD45 MicroBeads. Cells were stained using a conventional APAAP method followed by staining with hematoxylin. (Courtesy of Dr. Bilkenroth, Dept. Pathol. and Dr. Meye, Dept. Urol., Univ. Halle, Germany.)
Enrichment of tumor cells from a mixture of PBMCs and cells of the breast cancer cell line SK-BR3 using CD45 MicroBeads.
(A) Cell mixture before separation (7×106 PBMCs were spiked with 20,000 tumor cells)
(B) Negative fraction with enriched breast cancer cells
- Jiang, Y. et al. (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418: 41-49
- Meye, A. et al. (2002) Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. Int. J. Oncol. 21: 521-530
You have previously chosen International as your location.
What do you want to do?